Portal Veterinary medicinal products

The conference was organised in several sessions. In the first session, the context of the use of plants in veterinary medicine in the European Union was presented and the various stakeholders (farmers, veterinarians and pharmaceutical industries) were able to share their expectations and problems with the use of veterinary herbal medicines. Secondly, two experts from the Human Committee on Herbal Medicinal Products presented a feedback on the problems encountered in the authorisation of herbal medicinal products for human use compared to conventional chemical medicinal products. Then, the Anses-ANMV gave a feedback on the work carried out by France, in particular on the referral 2014-SA-0083 . Finally, these sessions continued with the presentation of the perspectives at European level by the EMA and the European Commission and the sharing of the views of the participants. Conference overview

The French agency for veterinary medicinal products (Anses-ANMV) organised with Ansm (French agency for human medicines) the second meeting of Heads of Agency (HMA) from 4 to 6 May. The meeting was held at the Palais du Grand Large in Saint Malo with 90 participants from the competent European authorities, the European Commission and the European Medicines Agency (EMA). On the first day, a meeting was organised with stakeholders: representatives of the veterinary medicine industry, veterinarians, farmers and the veterinary diagnosis industry. Among other things, the meeting provided an opportunity to discuss the implementation of the Veterinary Regulations. On May 5th and 6th, the heads of medicines agencies met for a day and a half. At the veterinary session, the European strategy HMA-EMA 2021-2025 on “Big Data” was adopted as well as the Action Plan of the Network of Agencies’ 2025 Strategy. Part of this event was dedicated to medical devices for human use.